Uniquity One (UNI)

Quick facts

Phase 2 pipeline

• Biological: Solrikitug high dose · Inflammation
  Solrikitug is a high-dose biologic that targets the IL-1β pathway.
• Biological: Solrikitug low dose · Inflammatory diseases
  Solrikitug is a low-dose biological drug that targets the IL-1β pathway.
• NSI-8226
• Solrikitug High Dose
• Solrikitug Low Dose
• Solrikitug Mid Dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Uniquity One (UNI) portfolio CI brief
• Uniquity One (UNI) pipeline updates RSS